Peak Bio, Inc. (PKBO) Stock Analysis
DELISTED 2023
What happened to Peak Bio, Inc. (PKBO) stock?
Peak Bio, Inc. (PKBO) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- January 2023
- Last recorded price (historical):
- $0.0225 (last quote on record before the January 2023 delisting; historical, not a current quote)
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Peak Bio, Inc. (PKBO). Peak Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for oncology and inflammation. Their lead candidate, PHP-303, is undergoing Phase II clinical study for Alpha1 anti-trypsin deficiency (AATD).
Last analyzed: Mar 17, 2026Dated analysis: the newest financial statements on file are 25 months old (Sep 1, 2024), so the figures and score below describe that period, not today.
Peak Bio, Inc. (PKBO) Healthcare & Pipeline Overview
More about this archive record
Can I still buy PKBO shares?
No. PKBO stopped trading on public markets in January 2023, so the shares are not available through a broker. Anything you see quoted for PKBO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PKBO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Peak Bio, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.